Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 816 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Butyrate Clear all
Completed Phase 2 Interventional Results available

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

NCT05508867
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
favezelimab/pembrolizumab, bendamustine, gemcitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 11:44 AM EDT
Not listed Early Phase 1 Interventional

Neuromodulation to Reduce Muscle Stiffness Following Spinal Cord Injury

NCT06274021
View directory record Official record
Conditions
Spinal Cord Injuries, Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic
Interventions
Transcutaneous spinal stimulation at 100 Hz, Transcutaneous spinal stimulation at 50 Hz, Transcutaneous spinal stimulation at 50 Hz and single dose of baclofen, Transcutaneous spinal stimulation at 50 Hz and single dose of tizanidine, Sham transcutaneous spinal stimulation
Device · Combination Product
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 2 Interventional Results available

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT02320487
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Bendamustine, Obinutuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
26
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 30, 2026, 11:44 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Gabapentin Treatment of Benzodiazepine Dependence

NCT01893632
View directory record Official record
Conditions
Benzodiazepine Dependence
Interventions
gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 30, 2026, 11:44 AM EDT
Recruiting Phase 2Phase 3 Interventional

Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children

NCT04724252
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Not applicable Interventional Results available

Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women

NCT02040532
View directory record Official record
Conditions
Menopause, Hot Flashes, Vasomotor Disturbance
Interventions
Gabapentin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Not applicable Interventional Results available

Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)

NCT01943435
View directory record Official record
Conditions
Lumbar Spinal Stenosis
Interventions
NSAIDs; adjunctive analgesics; adjunctive anti-depressants, Lumbar epidural injection, Joint Mobilizations (spine, sacroiliac, hip), Individualized exercises: clinical setting, Group Exercise: community setting
Drug · Procedure · Other
Lead sponsor
Michael Schneider, DC, PhD
Other
Eligibility
60 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 30, 2026, 11:44 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

NCT01732926
View directory record Official record
Conditions
Indolent Non-Hodgkin's Lymphomas
Interventions
Idelalisib, Rituximab, Bendamustine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Huntsville, Alabama • Chandler, Arizona • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Gut Butyrate and Blood Pressure in African Americans

NCT04415333
View directory record Official record
Conditions
Hypertension
Interventions
Sodium Butyrate 5 mmol, Sodium Butyrate 80 mmol
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 1 Interventional

Endothelial Dysfunction as a Risk Factor in HIV Study

NCT00039663
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin, Gemfibrozil, Rosiglitazone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 1Phase 2 Interventional Results available

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

NCT01664910
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine Hydrochloride, Fludarabine Phosphate, Inotuzumab Ozogamicin, Methotrexate, Peripheral Blood Stem Cell Transplantation, Rituximab, Tacrolimus
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 2 Interventional

Gabapentin and Tizanidine for Insomnia in Chronic Pain

NCT04429347
View directory record Official record
Conditions
Insomnia Due to Medical Condition, Chronic Pain
Interventions
Gabapentin, Placebo, Tizanidine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 30, 2026, 11:44 AM EDT
No Longer Available No phase listed Expanded access

Compassionate Use Re-Infusion of ATLCAR.CD30

NCT03914885
View directory record Official record
Conditions
Hodgkin Lymphoma, Adult
Interventions
ATLCAR.CD30, Bendamustine, Fludarabine
Genetic · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Enhancing Slow Wave Sleep With Sodium Oxybate

NCT00506974
View directory record Official record
Conditions
Sleep
Interventions
sodium oxybate
Drug
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Pain Associated With Fibromyalgia

NCT02187159
View directory record Official record
Conditions
Pain Associated With Fibromyalgia
Interventions
DS-5565, Pregabalin, Placebo tablet, Placebo capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Not applicable Interventional Results available

The Effect of Horizant (Gabapentin Enacarbil) on Augmentation

NCT02642315
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Horizant
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 3 Interventional Results available

Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).

NCT00413010
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
35
States / cities
Arcadia, California • Burbank, California • Redlands, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 2 Interventional

New Drugs in the Treatment of Mood Disorders

NCT00001482
View directory record Official record
Conditions
Anxiety Disorder, Mood Disorder, Psychotic Disorder
Interventions
Lamotrigine (Lamictal® (Registered Trademark), Gabapentin (Neurontin® (Registered Trademark))
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 30, 2026, 11:44 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

NCT06425302
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 11:44 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT01980888
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Idelalisib, Bendamustine, Rituximab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Fullerton, California • La Jolla, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Not applicable Interventional Results available

Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders

NCT05718583
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Butyrate
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 4 Interventional Results available

Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients

NCT02926573
View directory record Official record
Conditions
Head and Neck Cancer, Acute Pain, Postoperative Pain
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Not applicable Interventional

Dose-Response Study to Evaluate the Effect of BKR-017 on Insulin Resistance and Other Metabolic Parameters in Type 2 Diabetes Patients

NCT04673656
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
BKR-017
Dietary Supplement
Lead sponsor
BioKier Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Durham, North Carolina • Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 30, 2026, 11:44 AM EDT
Completed Phase 1 Interventional Results available

Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

NCT02148913
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cohort 1: Carfilzomib 15 mg/m2, Cohort 2: Carfilzomib 20 mg/m2, Cohort 2b: Carfilzomib 20 mg/m2, Cohort 3b: Carfilzomib 27 mg/m2
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 30, 2026, 11:44 AM EDT